A number of patients had to discontinue the study prematurely because of insulin administration (24.5% in the placebo and 14.2% in the acarbose group). There was a significant LS-mean difference ...

Objective: To assess the safety profile of acarbose treatment over a 1-year period at a dose range of 50 300mg three times daily in patients with type 1 or type 2 diabetes mellitus. Results ...